Hangwen LiChairman and CEO at Stemirna Therapeutics
Dr. Hangwen Li is the founder, chairman and CEO of Stemirna Therapeutics. He received his Ph.D degree in Cancer Biology from MD Anderson Cancer center of the University of Texas in 2010. Dr. Hangwen Li had nearly 20 years of research and treatment experience in the fields of tumor immunotherapy, RNA drugs and cancer stem cells, and had worked in clinical departments in the United States. He had worked in one of the best cancer hospital and tumor cell immunity center in the United States, and had won two awards for clinical transformation from the US Department of Defense. Currently he is an assistant professor in the Department of Pharmacology and Therapeutics of Roswell Cancer Center and also an expert in translational Medicine platform of Oriental Hospital affiliated to Tongji University in Shanghai.